AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.56
+2.58%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
Market Cap
$784.01M
MomentumView details →
1D Return
+2.58%
YTD Return
+37.25%
RSI (14)
49.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
Market Cap
$784.01M
RSI (14)
49.3
MomentumView details →
1D Return
+2.58%
YTD Return
+37.25%
SummaryUpdated Jun 1, 2026
Aura Biosciences, Inc. (NASDAQ:AURA) is a clinical-stage biotechnology company founded in 2009 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies using its proprietary virus-like drug conjugate (VDC) technology platform. Aura specializes in treating rare and difficult-to-treat cancers, particularly in ocular (eye-related) and urologic oncology where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
Aura Biosciences reported a net loss of $45.6 million for Q2 2026, with diluted EPS of -$0.48, and announced a 20% workforce reduction as part of an organizational realignment, expecting cash runway into the first half of 2029.25d agoAura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.59d ago